Sign in
Not yet taking people in United StatesNo phase

Spinal cord stimulation for severe restless legs syndrome that has not responded to treatment

Tests an implanted spinal cord stimulator in adults with severe restless legs syndrome.

Key facts

Who runs it
Marshall Holland
Where
Birmingham, United StatesSee the site
Trial code
Registry title
Neuromodulation to Overcome Severe Restless Legs Syndrome
Status
Not yet recruiting
People taking part
15 people, planned
Starts
Oct 2027
Expected to end
Oct 2034
Type of study
Interventional
Treatments tested
  • Spinal Cord Stimulation
Record updated
9 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with severe primary Restless Legs Syndrome (RLS) that has not improved enough with usual treatment. Participants get an implanted spinal cord stimulation device and are followed for 24 months.

Age
Over 18 years (minimum age 18 Years).
Sex
All sexes can join.
Disease stage
Severe RLS with an IRLS Scale score ≥ 21. Symptoms occur ≥ 3 nights per week. A sleep medicine doctor must find that standard RLS treatment did not work or did not work well enough.
Earlier treatment
Standard medical treatment for RLS must have failed or not helped enough. People who had a spinal cord stimulation trial or implant before cannot join.
Biomarker or test result
RLS diagnosis confirmed with the Cambridge Hopkins-RLS questionnaire and the Hopkins-Hening Diagnostic questionnaire. Ferritin must not be < 50 ng/mL. HgA1C must not be > 7.5.

Main reasons for not taking part

  • An active medical implant, such as a pacemaker, or another device used to treat RLS.
  • Nerve pain other than RLS, severe peripheral neuropathy, spinal cord injury or prior spine surgery.
  • Pregnant, breastfeeding, or trying to become pregnant.
  • Epilepsy, multiple sclerosis, Parkinson's disease or other severe movement disorder, deep vein thrombosis, or cancer within the past 5 years (except basal or squamous cell skin cancer).
  • Drug or alcohol abuse within the past year, severe psychiatric or memory disorder, or an active or chronic infection.

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Age >18 years and older
  • Received a medical diagnosis of RLS via first screening with Cambridge Hopkins- RLS questionnaire and confirmed via Hopkins-Hening Diagnostic questionnaire
  • IRLS Scale score ≥ 21 (classified as severe) and received a determination of treatment refractory RLS or inadequate response to standard medical treatment for RLS by a sleep medicine physician
  • RLS symptoms occur ≥ 3 nights per week
  • Willing and able to comply with study procedures
  • Able to provide informed consent

Who cannot take part

  • Active medical implant in the body (i.e., pacemaker)
  • History of prior SCS trial or implantation
  • Currently using another device to treat RLS
  • One or more of the following diagnoses: spinal cord injury or prior spinal surgery, severe peripheral neuropathy, severe psychiatric or cognitive disorder that may interfere with study participation, history of drug or alcohol abuse within the past year, epilepsy or seizure disorder, current active or chronic infection other than common cold, malignancy within the past 5 years (not including basal cell or squamous cell skin cancer), severe movement disorder (i.e., Parkinson's disease), deep vein thrombosis, multiple sclerosis, known or suspected allergy to SCS materials
  • Other medical conditions that would put the subject at risk as determined by the investigators
  • HgA1C > 7.5 (excludes unstable diabetes melilitus)
  • Age <18 years
  • Neuropathic pain, other than RLS on DN4 questionnaire
  • Any mental or physical limitation that would prevent completing and of the study protocols
  • Unable or unwilling to comply with study protocols
  • Pregnant, breastfeeding, or trying to become pregnant
  • Currently participating or plans to participate in any other investigational clinical evaluation during the study period that may, in the opinion of the investigators, affect RLS
  • Ferritin < 50 ng/mL (excludes iron deficiency)

Where in United States

  • UAB HospitalBirmingham, United StatesContact: Chris GonzalezNot yet recruiting

About the trial

What the trial wants to find out

This prospective, single-center, first-in-indication feasibility study will evaluate the safety and preliminary effectiveness of spinal cord stimulation (SCS) for the treatment of severe, treatment-refractory primary Restless Legs Syndrome (RLS). Participants will undergo implantation of the Saluda Medical Evoke® Spinal Cord Stimulation System and will be followed for 24 months with clinical, neurophysiological, and patient-reported outcome assessments.

The group in the trial

  • SCS ImplantTreatment being tested

    Treatment: Spinal Cord Stimulation

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Neuromodulation to Overcome Severe Restless Legs Syndrome (NO RLS)
Plain-language title
Spinal cord stimulation for severe restless legs syndrome that has not responded to treatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
9 October 2026